Lighthouse Pharmaceuticals
CompanyUnited States
Lighthouse Pharmaceuticals develops one asset, in phase 2 (LHP588 in Alzheimer disease due to p. gingivalis). Mostly small molecule; based in the United States.
- 1
- Asset
- Furthest stage
- Phase 2
- 2
- Grants
- 1
- Trial
- 2
- Signals
Pipeline
1Inhibitor targeting Porphyromonas gingivalis lysine-gingipain
Phase 2, Small molecule, Alzheimer disease due to p. gingivalis, Alzheimer's disease
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Trials1
- People1
- Signals2
- Similar companies6